Additionally, 40 Hz gamma-sensory stimulation has been investigated as a novel therapeutic approach, with studies demonstrating its potential to enhance glymphatic clearance of Aβ and reduce the microglial inflammatory response, synapse loss, amyloid plaque deposition, and tau pathology, thereby restoring cognitive function in AD mice (Adaikkan et al., 2019; Iaccarino et al., 2016; Martorell et al., 2019; Murdock et al., 2024). The gene discussed is MAPT; the disease is Alzheimer disease.